Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevimeline for Post-Radiation Xerostomia
NCT00017511Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2001
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in xerostomia comparing Cevimeline with Placebo (2 arms). Primary endpoints: Dryness of the oral cavity at 12 weeks and Salivary flow at 12 weeks. Started Jun 2001; status: completed.
02
Drugs
cevimeline
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT00017511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017511.